Emerging data highlights the potential of physiological peptides and hybrid agonists to revolutionize therapeutic interventions for metabolic diseases. These advanced compounds offer the unique capacity to simultaneously engage multiple targets, circumventing the drawbacks of traditional mono-therapy treatments. By modulating tissue signaling, they